Form 4: OrbiMed Advisors LLC Reduces Stake in Passage Bio, Inc.

OrbiMed Advisors LLC has sold a portion of its holdings in Passage Bio, Inc. over three days, reducing its indirect ownership.

Summary

• OrbiMed Advisors LLC, along with OrbiMed Capital GP VII LLC, has reported the sale of Passage Bio, Inc. common stock.
• The sales occurred over three days, from December 9th to December 11th, 2024.
• A total of 62,276 shares were sold at prices ranging from $0.80 to $0.87 per share.
• The sales reduced OrbiMed's indirect holdings from 7,643,285 to 7,635,190 shares.
• The shares are held by OrbiMed Private Investments VII, LP, with OrbiMed Capital GP VII LLC as the general partner and OrbiMed Advisors LLC as the managing member.

Sentiment

Score: 4

Explanation: The document indicates a reduction in ownership by a major shareholder, which is generally viewed negatively by the market. However, the sales are not large enough to indicate a major concern.

Negatives

• OrbiMed Advisors LLC has reduced its stake in Passage Bio, Inc., which could be interpreted negatively by the market.

Risks

• Continued selling by OrbiMed could put downward pressure on Passage Bio, Inc.'s stock price.
• The reasons for the sale are not disclosed, which could lead to speculation and uncertainty.

Management Comments

• Carl L. Gordon, Member of OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, signed the report.

Industry Context

This transaction is a routine disclosure of stock sales by a major shareholder and is common in the biotech industry where investment firms often adjust their holdings.

Comparison to Industry Standards

• Similar transactions are regularly reported by investment firms in the biotech sector, such as those by RA Capital Management or Baker Bros. Advisors.
• These types of sales are often part of portfolio management strategies and are not necessarily indicative of a negative outlook on the company.

Stakeholder Impact

• The sale of shares may cause a slight decrease in the stock price, impacting shareholders.
• The reduction in ownership by a major investor could lead to uncertainty among other stakeholders.

Key Dates

Keywords

OrbiMed Advisors, Passage Bio, Stock Sale, Beneficial Ownership, SEC Form 4, Share Transaction